Tedizolid Phosphate

Tedizolid Phosphate

SCHEMBL1990278

Cn1nnc(-c2ccc(-c3ccc(N4CC(COP(=O)(O)O)OC4=O)cc3F)cn2)n1

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Tedizolid Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAOA P21397 12/20 0.79
MAOB P27338 2/20 0.79
CALML3 P27482 6/20 0.48
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tedizolid Phosphate SCHEMBL29377855 1.00 MAOA (0.79) MAOAMAOBCALML3CYP2C19CYP2C9
Tedizolid Phosphate SCHEMBL29766931 1.00 MAOA (0.79) MAOAMAOBCALML3CYP2C19CYP2C9
Tedizolid Phosphate SCHEMBL1557561 1.00 MAOA (0.79) MAOAMAOBCALML3CYP2C19CYP2C9
SCHEMBL20216092 0.96 MAOA (0.81) MAOAMAOBCALML3CYP2C19CYP2C9
SCHEMBL13144441 0.96 MAOA (0.81) MAOAMAOBCALML3CYP2C19CYP2C9
SCHEMBL1990275 0.95 MAOA (0.82) MAOAMAOBCALML3CYP2C19CYP2C9
SCHEMBL13144426 0.95 MAOA (0.76) MAOAMAOBCALML3CYP2C19CYP2C9
SCHEMBL2189136 0.95 MAOA (0.76) MAOAMAOBCALML3CYP2C19CYP2C9
SCHEMBL12997802 0.95 MAOA (0.78) MAOAMAOBCALML3CYP2C19CYP2C9
SCHEMBL12997803 0.95 MAOA (0.78) MAOAMAOBCALML3CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4444275-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2024-10-16 EP claimed
WO-2023104380-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2023-06-15 WO claimed
EP-4190312-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES Karlsruher Institut für Technologie (DE) 2023-06-07 EP claimed
EP-1699784-B1 NOVEL OXAZOLIDINONE DERIVATIVES DONG A PHARM CO LTD (KR) 2011-06-29 EP claimed
CN-120001315-A Texazolamide phosphate preparation device for injection 安徽省诚联医药科技有限公司 2025-05-16 CN disclosed
CN-119701726-A Preparation device of tedizolid key intermediate 苏州艾培瑞生物科技有限公司 2025-03-28 CN disclosed
EP-4444275-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2024-10-16 EP disclosed
CN-117959311-A Application of tedizolid phosphate in preparation of cisplatin-resistant ototoxic drugs 山东第一医科大学(山东省医学科学院) 2024-05-03 CN disclosed
CN-115385959-B High-purity tedizolid phosphate and preparation method thereof 浙江尖峰药业有限公司 2023-07-28 CN disclosed
WO-2023104380-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES Karlsruher Institut für Technologie (DE) 2023-06-15 WO disclosed
CN-116253711-A Texazolamide phosphate intermediate and preparation method thereof 浙江苏泊尔制药有限公司 2023-06-13 CN disclosed
EP-4190312-A1 SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES Karlsruher Institut für Technologie (DE) 2023-06-07 EP disclosed
CN-105837634-B Tedizolid phosphate crystal and preparation method thereof 上海创诺制药有限公司 2020-09-04 CN disclosed
CN-106146485-A A kind of method preparing safe ground azoles amine and the safe ground azoles amine crystalline solid obtained thereof 上海创诺医药集团有限公司 2016-11-23 CN disclosed
CN-105985331-A Process for preparing tedizolid 上海医药工业研究院 2016-10-05 CN disclosed
CN-105859780-A Method for preparing tedizolid phosphate 山东康美乐医药科技有限公司 2016-08-17 CN disclosed
CN-105837634-A Tedizolid phosphate crystal and preparation method thereof 上海创诺制药有限公司 2016-08-10 CN disclosed
US-20140057874-A1 OXAZOLIDINONE CONTAINING DIMER COMPOUNDS, COMPOSITIONS AND METHODS TO MAKE AND USE TRIUS THERAPEUTICS, INC. (US) 2014-02-27 US disclosed
US-8580767-B2 Oxazolidinone containing dimer compounds, compositions and methods to make and use TRIUS THERAPEUTICS, INC. (US) 2013-11-12 US disclosed
WO-2010138649-A1 OXAZOLIDINONE CONTAINING DIMER COMPOUNDS, COMPOSITIONS AND METHODS TO MAKE AND USE TRIUS THERAPEUTICS, INC. (US) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057874-A1 OXAZOLIDINONE CONTAINING DIMER COMPOUNDS, COMPOSITIONS AND METHODS TO MAKE AND USE NR1I2, NR1D2, NR1D1 MAOA 3015/4885MAOB 2265/4885CALML3 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.